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Abstract
Background: The aim of this study was to investigate the molecular characteristics of isoniazid resistant
Mycobacterium tuberculosis (MTB), as well as its contribution to the dissemination of multi-drug resistant TB
(MDR-TB) in rural areas of eastern China.
Methods: A population-based epidemiological study was conducted in two rural counties of eastern China from
2004 to 2005. In total, 131 isoniazid resistant MTB isolates were molecularly characterized by DNA sequencing and
genotyped by IS6110 restriction fragment length polymorphism (RFLP) and spoligotyping.
Results: The katG315Thr mutation was observed in 74 of 131 isoniazid resistant isolates and more likely to be
MDR-TB (48.6%) and have mutations in rpoB gene (47.3%). Spoligotyping identified 80.2% of isoniazid resistant MTB
isolates as belonging to the Beijing family. Cluster analysis by genotyping based on IS6110 RFLP, showed that
48.1% isoniazid resistant isolates were grouped into 26 clusters and katG315Thr mutants had a significantly higher
clustering proportion compared to those with katG wild type (73%.vs.18%; OR, 12.70; 95%CI, 6.357-14.80). Thirty-one
of the 53 MDR-TB isolates were observed in 19 clusters. Of these clusters, isoniazid resistance in MDR-TB isolates
was all due to the katG315Thr mutation; 18 clusters also contained mono-isoniazid resistant and other isoniazid
resistant isolates.
Conclusions: These results highlighted that isoniazid resistant MTB especially with katG315Thr is likely to be
clustered in a community, develop extra resistance to rifampicin and become MDR-TB in Chinese rural settings.
Background
Isoniazid (INH) is one of the most effective and specific
agents for the treatment of the disease caused by Myco-
bacterium tuberculosis (MTB). It is a cornerstone of the
modern short-course chemotherapy for tuberculosis,
and also widely used to treat the latent MTB infection
(LTBI) to prevent the active disease and the subsequent
TB transmission.
However, recent increases both in INH-resistant and
multidrug-resistant (MDR) tuberculosis have been jeo-
pardizing the efforts of global TB control through the
implementation of the Directly Observed Treatment,
Short course (DOTS) [1,2].I nC h i n a ,D O T Sp r o g r a m
has been adopted since early 1990s, but the increased
prevalence of drug resistant TB has become a significant
challenge for TB control in last ten years. The preva-
lence of MDR-TB and INH resistant TB was estimated
as 8.3% and 41.2% respectively among all cases in
China, which were both high compared to the global
estimates of 4.8% and 13.3% [3].
The development of INH resistance is a common first
step in the evolution to MDR [4]. Thus, there has been
considerable interest in both identifying the molecular
basis of INH resistance and understanding the transmis-
sion pattern of the INH resistant MTB strain.
Resistance to INH is mediated by mutations in differ-
ent genes in MTB, with katG [5] and inhA [6] being the
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major mechanism of INH resistance in MTB [7-9]. The
most common mutation is the Ser315Thr substitution
in the katG gene, which is present in approximately 50-
90% of all INH-resistant isolates and is associated with
relatively high-level resistance to INH [9]. The mutation
in inhA or its promoter region can cause 21-24% of
INH resistance, with the promoter mutation (mainly in
the inhA-15 position) being more common than the
mutation in the structural gene [8]. A study of INH
resistance in MTB has reported that a certain INH resis-
tant strain with the katG315Thr mutation had a strong
association with the development of MDR, and the suc-
cessful transmission of MDR MTB as well [10].
Based on the above knowledge and findings, we
hypothesized that specific INH resistant MTB strains
could perpetuate the epidemic of MDR-TB in high TB
burden countries like China.
Here we presented an in-depth study to determine the
molecular basis of INH-resistant MTB and the transmis-
sion pattern of INH resistant MTB circulating in two
rural counties of eastern China. We applied direct DNA
sequencing on hotspots of katG and inhA genes/promo-
ters as well as the IS6110 restriction fragment length
polymorphism (RFLP) genotyping technique to analyze
the level of clustering or recent transmission of INH-
resistant MTB. Combined with epidemiological evi-
dence, the molecular information obtained from this
study could give us a better understanding of the possi-
ble mechanism behind the high prevalence of MDR-TB
in rural China.
Methods
Study population
The epidemiological methods and study population of
this study were described previously [11]. It is a popula-
tion-based cross-sectional study carried out in two rural
counties in eastern China, i.e., Deqing County in Zhe-
jiang Province and Guanyun County in Jiangsu Province.
All TB patients notified in the County TB dispensaries
within one year were enrolled in the study (Deqing,
from April 1, 2004 to March 31, 2005; Guanyun, from
June 1, 2004 to May 31, 2005).
Drug susceptibility test
All MTB isolates were tested for drug susceptibility
using the proportion method on egg-based LJ medium
[12]. The critical drug concentration were 0.2 μg/ml for
isoniazid (INH), 40 μg/ml for rifampicin (RIF), 4 μg/ml
for streptomycin (STR) and 2 μg/ml for ethambutol
(EMB). Resistance was defined as the growth of more
than 1% colonies compared to the drug free control.
MDR was defined as drug resistance to at least INH and
RIF. Poly drug-resistance was defined as resistance to
more than one of the tested anti-TB drugs but not to
both INH and RIF simultaneously.
DNA sequencing
All isolates available were investigated for the presence of
the hotspot mutations related to drug resistance by direct
DNA sequencing. The hotspot genes included rpoB, katG
genes and the inhA promoter region, corresponding to
the drug resistance to RIF and INH respectively. The Pri-
mers pairs were CCCATGGCCGCGGCGGTCGACATT
and CGCCGTCCTTGGCGGTGTATTGCC for katG
gene (GeneBank: X68081), and CCTCGCTGCCCA-
GAAAGGGA and ATCCCCCGGTTTCCTCCGGT for
inhA promoter region (GeneBank: U41388), and
GGGAGCGGATGACCACCCA and GCGGTACGG-
CGTTTCGATGAAC for rpoB gene (GeneBank: L27989).
Mutations in these genes were determined by amplifica-
tion of the corresponding hotspot DNA region by PCR
followed by direct DNA sequencing with ABI 3770 DNA
sequencer (Applied Biosystems, Inc., Foster City, CA,
USA). The new alleles were confirmed by further PCR
and re-sequencing from the original DNA. Sequencing
data was independently analyzed by two biologists for
quality control purposes.
IS6110-RFLP genotyping
IS6110 RFLP was done on the INH resistant isolates
according to the standard protocol of van Embden et al,
with data analyzed by the Gel Compar software (version
4.6, Applied Maths, Belgium) [13]. A cluster is defined
as two patient MTB isolates harboring the identical
IS6110 RFLP pattern. Unique strains denote unparallel-
ness of the IS6110 RFLP profiles in the study collection.
Typically, clustered strains indicate recent transmission
while unique strains indicate reactive disease from a
remote infection.
Spoligotyping
Spoligotyping was carried outb yu s i n gt h ec o m m e r c i a l
k i tf r o mI s o g e nB i o s c i e n c eB V( M a a r s s e n ,T h eN e t h e r -
lands) [10]. The INH resistant strain clades were deter-
mined by comparison of the spoligotyping pattern with
the SpolDB3 database [14] in the SpotClust program
(available in http://cgi2.cs.rpi.edu/~bennek/SPOT-
CLUST.html) and assigned with the corresponding spo-
ligotype international type (SIT). The Beijing family
MTB was defined as the strain that hybridized only to
the last nine spacer oligonucleotides (spacers 35 to 43).
Statistics analysis
SPSS software (SPSS Inc., Chicago, IL, USA) was utilized
for the statistics analysis. Clinical and bacteriological
characteristics were compared between katG315Thr
alleles and other INH resistant isolates using the
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sion model was used for univariate and multivariate
analysis to qualify and quantify the difference in cluster-
ing proportion between groups of subjects with different
socio-demographic and clinical characteristics. The
adjusted Odds Ratio (OR) and 95% confidence interval
(CI) were calculated by adjusting for the possible con-
founders (age, county and sex).
The study was approved by the Institutional Review
Board of Fudan School of Public Health. Written
informed consent was obtained from all the participants.
Results
In total, drug resistance profile and baseline information
were successfully obtained from 399 pulmonary TB
patients, 182 in Deqing and 217 in Guanyun during the
study period. Of the 399 MTB isolates from these
patients, 251 (62.9%) were resistant to at least one of 1
st
line anti-TB drugs. Resistance to INH was the most
common form of drug resistance (140/251) with a
majority of cases mono-resistant to INH (55/140). Resis-
tance to RIF was observed in 65 isolates, only 2 of
which were mono-resistant. A total of 58 isolates were
resistant to INH and RIF simultaneously. The details of
the resistance have been reported previously [11].
DNA samples were successfully extracted from 131 of
the 140 INH resistant isolates. Of the 131 isolates, 80
were from patients who were previously diagnosed with
TB and 51 were from the patients newly diagnosed.
Regarding the drug resistance profile, apart from the 55
INH mono-resistant isolates, 53 were also resistant to
RIF and referred to as MDR-TB; 23 were poly-resistant
(INH + STR and/or EMB) (Table 1).
DNA sequencing demonstrated that 107 of 131 INH
resistant isolates had mutations either in the katG gene
or in the inhA promoter (Table 2): 61.8% (81/131) of
the isolates had a mutation in the position 315 of katG,
of which 56.5% (74/131) INH resistant isolates con-
tained the katG Ser315Thr nucleotide substitution. kat-
G315Arg and katG315Asn mutations were detected in 3
and 4 isolates respectively. In addition, 28 of 131 INH
resistant isolates (21.4%) presented the mutation in the
inhA promoter region, all of which possessed the inhA-
15 C®T nucleotide substitution. Two INH resistant
isolates shared the mutation in katG and inhA gene
simultaneously: one with katG 315Thr and inhA-15T
mutations and the other with katG315Arg and inhA-
15T mutations. No nucleotide substitutions were identi-
fied in 220 INH sensitive isolates either at the katG315
position or the inhA-15 position. The frequency of the
katG315Thr mutation was significantly higher in MDR-
TB compared to the other drug resistant form of MTB
isolates (67.9%.vs.48.7%; c
2, 4.736; p, 0.030), while inhA-
15T mutations did not differ significantly between these
two major drug susceptibility groups (20.8%.vs.21.8%; c
2,
0.020; p, 0.887).
The resistance to RIF was due to mutations in the
rpoB gene in 49 of 53 MDR-TB isolates. A single-
nucleotide substitution in position 516, 526 and 531
accounted for 7.5%, 30.2% and 58.5% respectively of
MDR-TB. The mutations in rpoB gene included 516Tyr
(3/53), 516Val (2/53), 526Arg (4/53), 526Tyr (11/53)
and 531Leu (31/53). Double-spot mutations were pre-
sented in two MDR isolates, one with 516Tyr/531Leu
mutations and the other with 516Val/531Leu mutations.
Table 1 Drug susceptibility profile of INH resistant MTB
isolates from the study sites
Drug
resistance
profile
Total
n = 131
No. of isolates
from patients with:
newly
diagnosed TB
n =8 0
previously
diagnosed TB
n =5 1
H5 5 3 0 2 5
MDR-TB 53 33 20
HR 32 21 11
HRS 12 6 6
HRE 5 3 2
HRSE 4 3 1
PDR-TB 23 17 6
HS 13 9 4
HE 2 1 1
HSE 8 7 1
NOTE: H, isoniazid; R, rifampicin; S, streptomycin; E, ethambutol;
MDR-TB, multidrug-resistant tuberculosis; PDR-TB, polydrug-resistant
tuberculosis.
Table 2 Genetic mutations and their frequencies related
to INH resistance in MTB isolates from the study sites
Drug resistance Total katG315Ser → * inhA -15C→ * katG +w t
Profile Arg Asn Thr T inhA
§
H5 5 2 1 2 8 1 2 0 1 2
MDR-TB
HR 32 0 1 19 6 1 5
HRS 12 0 0 9 2 1 0
HRE 5 0 0 5 0 0 0
HRSE 4 0 1 2 1 0 0
PDR-TB
HS 13 0 0 5 3 0 5
HE 2 0 0 0 1 0 1
HSE 8 0 1 5 1 0 1
NOTE: H, isoniazid; R, rifampicin; S, streptomycin; E, ethambutol.
MDR-TB, multidrug-resistant tuberculosis; PDR-TB, polydrug-resistant
tuberculosis.
*: No. of isolates with mutations in single gene.
§: No. of isolates with mutations in multiple genes. Two INH resistant isolates
shared the mutation in katG and inhA gene simultaneously: one with
katG315Thr and inhA-15T mutations and the other with katG315Arg and inhA-
15T mutation.
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to RIF.
MTB clades designations were available for 122 of 131
isolates, with the following distribution of the genotypic
lineages (Table 3): Beijing family (105/131 or 80.1%),
Family 33 (8/131 or 6.1%), T lineage (7/131 or 5.3%),
Haarlem (1/131 or 0.8%) and LAM (1/131 or 0.8%). Of
the remaining 9 isolates, 6 had the spoligotyping pattern
similar to T lineage, 1 similar to Family 33, 1 similar to
Haarlem and 1 similar to LAM.
In the clustering analysis of INH resistant isolates
specific to counties (Figure 1), IS6110 RFLP identified
all together 94 IS6110 RFLP patterns, including 11
cluster patterns (27 isolates), 28 unique patterns/iso-
lates in Deqing, 15 cluster patterns (36 isolates) and 40
unique patterns/isolates in Guanyun. The genotype
and phenotype patterns of drug resistant TB were
further investigated among the clustered isolates. Ten
clusters (25 isolates) from Deqing and 12 clusters (32
isolates) from Guanyun contained isolates with differ-
ent phenotype and/or genotype of drug resistance. In
these clusters, INH resistant isolates with the
katG315Thr mutation had the highest occurrence (51/
5 7o r8 9 . 5 % ) .A d d i t i o n a l l y ,3 1o f5 3M D R - T Bi s o l a t e s
(58.5%) were observed in 19 clusters, with all carrying
the katG315Thr mutation as well as the mutations
either in position 516, 526 or 531 of the rpoB gene. In
these clusters containing MDR-TB isolates, 18 clusters
had INH-mono resistant and/or polydrug-resistant TB
isolates simultaneously.
Binary logistic regression was applied to analyze the
“clustering” of INH resistant isolates in association with
patients’ demographics, clinic profiles and the bacterio-
logic features (Table 4). Smear-positive TB patients had
a significantly higher proportion of clustered INH resis-
tant MTB strain than smear-negative patients (54.9%.
vs.36.7%; adjusted OR, 2.286; p, 0.032; 95%CI,1.075-
4.863), as well as the previously diagnosed patients
when compared to newly diagnosed patients (60.8%.
vs.40.0%; adjusted OR, 2.159; p, 0.040; 95%CI,1.037-
4.495). A significant higher proportion of MDR-TB iso-
lates was clustered compared to INH mono resistant
isolates (58.5%.vs.38.2%; adjusted OR, 2.384; p, 0.030;
95%CI, 1.089-5.220). Compared with the wild type (wt)
isolates, the isolates with the katG315Thr mutation were
more likely to be clustered (73.0%.vs.18.0%; adjusted OR,
12.70; p, 0.001; 95%CI, 6.357-14.80). The Beijing family
isolates was mainly observed in clusters (56.2%.vs.15.4%;
adjusted OR, 5.289; p,0 . 0 0 1 ;9 5 % C I ,1 . 8 3 2 - 1 5 . 2 6 ) .T h e
INH resistant inhA-15T mutant isolates were more
likely to be “unique” compared to those inhA-15 wild
type isolates (14.3%.vs.57.3%; adjusted OR, 0.120;
p, 0.001; 95CI%, 0.038-0.375).
To further investigate the characteristics of
katG315Thr mutant, the host and bacteriological vari-
able were compared between the INH resistant isolates
with the katG315Thr mutation group and those with
other mutation/wild type group (Table 5). The
katG315Thr mutant isolates had a significantly higher
proportion of MDR-TB (48.6%.vs.29.8%; p, 0.03), the
relevant mutation in rpoB gene (47.3%.vs.24.6%,
p, 0.008) compared to other mutation/wild type group.
And meanwhile, this allele was more likely to be clus-
tered (73.0%.vs.15.8%; p, 0.001) and belonged to the
Beijing family (87.8%.vs. 70.2%; p, 0.012).
Discussion
This study attempted to gain further insight into the
molecular basis of the INH resistant MTB circulating
in the rural area of eastern China. Transmission of
INH resistant MTB and its possible contribution to
the epidemic of MDR-TB were also a concern. The
majority of INH strains from TB dispensaries in the
rural Chinese area, exhibited INH mono-resistance and
the double-drug-resistance profile especially including
extra resistance to RIF (53/131) and STR (37/131).
These resistance profiles corroborated the pattern of
acquisition of resistance to extra drug resistance espe-
cially for RIF and STR in INH resistant isolates [1].
Table 3 Spoligotyping pattern and frequency of the MTB
isolates included
Octal designation Clade* Probability
§ SIT No. of isolates
0000 0000 0003 771 Beijing 0.99 1 105
5777 7777 7760 771 T1 0.99 334 2
7777 7777 7760 031 T1 0.99 239 1
7777 7777 7760 771 T1 0.99 53 4
7777 7736 7730 771 T1 0.79 new 1
7777 2737 7730 771 T1 0.79 new 1
7777 7777 7730 771 T1 0.79 2597 1
7577 3737 7730 771 T1 0.79 new 1
7736 3737 7730 771 T1 0.79 new 1
7736 7777 7730 771 T1 0.79 new 1
7777 7777 7146 741 Family33 0.99 new 1
5777 7763 3566 731 Family33 0.99 new 1
7767 6767 1146 771 family33 0.99 new 1
7777 7377 7731 771 family33 0.99 new 2
7777 7777 1146 771 family33 0.99 new 1
7777 3717 7733 571 Family33 0.99 new 1
7777 3771 7731 761 Family33 0.99 new 1
7777 7777 7630 771 Family33 0.70 new 1
7777 7777 6000 371 Haarlem1 0.98 1498 1
5777 7777 7700 771 Haarlem3 0.77 new 1
7777 7760 3560 731 LAM9 0.99 new 1
6777 7760 7560 771 LAM1 0.51 1755 1
NOTE: SIT, spoligotype international type.
*: Spotclust program-assigned clade.
§: Probability that the spoligotyping pattern belongs to the clade.
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strains around the world varies, especially with regard to
the prevalence of TB. High TB burden regions [15-17]
always observe a higher prevalence of the katG315Thr
mutation in INH resistant strain compared to low TB
burden areas [18-20]. The present study also demon-
strated a high prevalence of the katG 315Thr mutant
allele in eastern rural China in around 50% of INH resis-
tant isolates, which is consistent with the other report
from China [21]. Furthermore in the current study, a sig-
nificant correlation was confirmed between the common
katG315Thr mutation in INH resistant strains and the
presence of resistance to other drugs, especially for RIF.
These observations might suggest that the INH resistant
strain with the katG315Thr mutation may be more likely
to develop the resistance to other 1
st line drugs especially
for RIF [22-24] than the strains with other forms of INH-
resistance. Meanwhile, the high proportion of INH resis-
tant katG 315Thr mutant allele bore the mutation in
rpoB gene, which was related to RIF resistance reported
i nC h i n a[ 2 5 ]a n dc o u l db et h er e a s o n sf o rt h eh i g hr i s k
of developing MDR in this allele.
The extensive transmission of the INH resistant MTB
strain was observed in rural areas of eastern China, with
48.1% of the INH resistant MTB isolates in clusters.
Most of INH resistant isolates with katG mutations
were in clusters compared to wild type INH resistant
isolates, suggesting its strong transmissibility, full viru-
lence and survival advantage under the drug pressure in
the host. This could be explained by the maintenance of
the 30%~40% catalase-peroxidase activity in the INH
resistant strain with the katG 315 Thr mutation [5,6]
compared to other mutations related to drug resistance.
Consequently, this allele was suspected as the cause of
some earlier reported outbreaks [26-28] of INH resistant
TB in specific areas and populations. Furthermore, the
c u r r e n ts t u d yo b s e r v e dt h a ti nac l u s t e rc o n t a i n i n g
strains with different drug resistance profile and
Figure 1 The phenotypes and genotypes of INH resistant MTB isolates with cluster and unique pattern respectively in Deqing and
Guanyun. NOTE. DR, 1
st line Drug resistance profile. *: The circle contained the code for the cluster. §: Sequence of drugs was isoniazid,
rifampicin, streptomycin, ethambutol; R, resistant; S, susceptible.
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caused by this mutation. This increased the possibility
that the INH resistant MTB strain with the katG 315
mutation in the index person was more likely to experi-
ence a series of subsequent mutations, leading to the
accumulation of extra drug resistance and the develop-
ment of MDR- and/or extreme drug resistant(XDR)-TB
[29]. The accumulation of drug resistance could be
accredited by less efficiencies of standard chemotherapy,
the subsequent mutation of drug resistance-related gene
and selective survival of drug resistant strain during the
recent transmission.
Apart from the role of the katG315Thr mutation, the
transmissibility of INH resistant strain might be related
to endemic characteristics of the Beijing family in rural
China. The Beijing genotype is apparently the most pre-
valent genotype in China, representing of 80.2% INH
resistant and 83% MDR-TB isolates in the current
study. Our study also found that the MTB strain from
the Beijing family was also the main source of recent
transmission causing INH resistant TB. The Beijing gen-
otype has been reported to be associated with treatment
failure and relapse. Although the reasons for this are
not known, it appears that the infections with the Beij-
ing genotype strain may be more persistent, probably
leading to longer duration of infectiousness and creating
a better opportunity for transmission under the anti-TB
drug pressure [30].
Additionally in the current study, INH resistant MTB
was more likely to be clustered in smear-positive and
previously diagnosed patients. The smear-positive status
might extend the transmission period of the pathogen
between hosts and allow MTB to attack more people in
the surroundings of the index case. Although the pre-
vious TB could be cured by direct observed chemother-
apy, those formerly treated cases could still be at risk
Table 4 Binary logistic regression analysis on the associations between demographical, clinical and bacteriological
characteristics and clustering of INH resistant MTB isolates in the present study
Variables INH resistant isolates unadjusted
OR
adjusted
OR*
p 95%CI
No. patients n (%) clustered
Social-demographic and clinical characteristics:
Age (year) 18~ 34 12(35.3) 1
30~ 65 34(52.3) 2.011
60~ 32 17(53.1) 2.078
Sex Female 46 22(47.8) 1
Male 85 41(48.2) 1.163
County Deqing 55 27(49.1) 1
Guanyun 76 36(47.4) 0.933
BMI ≥18.5 94 41(43.6) 1 1
Index <18.5 37 22(59.5) 1.896 1.833 0.13 0.836-4.019
Treatment New 80 32(40.0) 1 1
history Previously 51 31(60.8) 2.325 2.159 0.040
§ 1.037-4.495
Sputum negative 49 18(36.7) 1 1
smear positive 82 45(54.9) 2.095 2.286 0.032
§ 1.075-4.863
Cavity No 111 50(45.0) 1 1
Yes 20 13(65.0) 2.266 2.423 0.091 0.868-6.761
Bacteriological features:
Drug INH mono 55 21(38.2) 1 1
resistance MDR-TB 53 31(58.5) 2.281 2.384 0.030
§ 1.089-5.220
PDR -TB 23 11(47.8) 1.484 1.627 0.348 0.588-4.496
katG wt 50 9(18.0) 1 1
315Thr 74 54(73.0) 12.3 12.7 0.001
§ 6.357-14.80
others 7 0(0) - -
inhA wt 103 59(57.3) 1 1
-15T 28 4(14.3) 0.124 0.12 0.001
§ 0.038-0.375
Beijing No 26 4(15.4) 1 1
genotype Yes 105 59(56.2) 5.183 5.289 0.001
§ 1.832-15.26
NOTE. OR, odds ratio; 95%CI, confidence interval; wt, wild type; MDR-TB, multidrug-resistant tuberculosis; PDR-TB, polydrug-resistant tuberculosis.
*: OR and 95%CI were adjusted by age, sex and county of subjects in binary logistic regression model.
§: p <0 . 0 5 .
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the risk factors for TB (low socio-economic status,
exposure to MTB etc.) are still present. In combination
with these conditions, the risk of INH resistant MTB
transmission between hosts increases.
The epidemic of MDR-TB can occur as a result of the
spontaneous mutations in MTB and selection under
suboptimal drug therapy or extensive transmission of
the drug resistant MTB, or both combined. In the cur-
rent study, a significant high proportion of MDR-TB
isolates were observed in clusters compared to the other
form of INH mono-resistant isolates. Most clusters with
MDR-TB isolates also contained isolates with other drug
resistance profiles including INH mono-resistance and
poly drug-resistant tuberculosis simultaneously. Based
on these observations, the epidemic of MDR-TB in rural
China could be explained by two possibilities: 1) the epi-
demic of MDR-TB might result from the recent trans-
m i s s i o no fM D R - T Bs t r a i n si na na r e ar i d d e nb yI N H
resistant MTB. 2) Recent transmission of the drug resis-
tant MTB and the selection of MTB under drug pres-
sure might exert the symbiotic interaction in an
epidemic of MDR-TB. The combination of INH resis-
tance and maintained virulence might make it possible
for some INH resistant strains, especially those with the
katG315Thr mutation, to acquire extra drug resistance
and become MDR-TB. It deserves further investigation
to determine which mechanism may play the critical
role in the epidemic of MDR-TB, since the implication
behind it could be meaningful to evaluate the perfor-
mance of local TB control as well as to determine the
MDR-TB control strategies suitable for rural areas of
China and as well as other similar high burden settings.
Conclusions
INH resistant MTB was transmitted widely in eastern
rural areas of China. Also the correlation of prevalence
and transmission between INH resistant isolates espe-
cially with the katG315Thr mutation and MDR-TB was
confirmed. Therefore, it is important to recognize the
katG315Thr mutants among INH-resistant strains, which
could be seen as a risk factor for subsequent develop-
ment of MDR-TB. Early detection of the patients with
INH resistant strains would facilitate the modification of
treatment regimens and appropriate infection control
measures can be taken in time to reduce the risk of
further development and transmission of MDR-TB.
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